7 results
8-K
EX-99.2
PASG
Passage Bio Inc
4 Aug 22
Passage Bio Reports Second Quarter 2022 Financial Results and Provides Recent Business Highlights
7:20am
StrategyCreating sustainable value across rare and large, monogenic and non-monogenic CNS indicationsCutting-edge R&D ADULT (RARE, MONOGENIC)ADULT (NON-MONOGENIC
8-K
EX-99.2
PASG
Passage Bio Inc
16 May 22
Passage Bio Reports First Quarter 2022 Financial Results and Provides Recent Business Highlights
7:15am
sustainable value across rare and large, monogenic and non-monogenic CNS indicationsCutting-edge R&D ADULT (RARE, MONOGENIC)ADULT (NON-MONOGENIC)PEDIATRIC (RARE
8-K
EX-99.2
PASG
Passage Bio Inc
10 Jan 22
Passage Bio Announces 2022 Research and Clinical Development Goals to Advance Robust CNS Pipeline
8:00am
natural history study of infantile and juvenile GM1 gangliosidosis patients
6 A Diversified Portfolio StrategyCreating sustainable value across rare
10-Q
2020 Q1
EX-10.2
PASG
Passage Bio Inc
11 May 20
Quarterly report
4:06pm
, and sustainable guidelines and procedures, using new or comparable materials only, by a contractor reasonably approved in writing by Landlord, and on days
S-1
EX-10.5
qm3pzpqfn30qf6d sn
3 Feb 20
IPO registration
6:39am
DRS/A
EX-10.5
m7nyvbj3q0k3f8d2
10 Jan 20
Draft registration statement (amended)
12:00am
- Prev
- 1
- Next